Pfizer Inc. (NYSE:PFE) Shares Sold by Bath Savings Trust Co

Bath Savings Trust Co lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 64.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,386 shares of the biopharmaceutical company's stock after selling 27,842 shares during the quarter. Bath Savings Trust Co's holdings in Pfizer were worth $390,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC raised its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter worth $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PFE. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 0.0%

PFE traded up $0.01 during trading hours on Friday, reaching $23.46. 56,576,195 shares of the stock traded hands, compared to its average volume of 41,090,161. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a market cap of $133.38 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm's fifty day simple moving average is $23.12 and its two-hundred day simple moving average is $25.06.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the company posted $0.82 earnings per share. The company's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.33%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.